What is the recommended dosing protocol for vasopressin infusion in an adult patient with vasoplegic syndrome following cardiopulmonary bypass?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vasopressin Dosing for Post-Bypass Vasoplegia

For vasoplegic syndrome after cardiopulmonary bypass, start vasopressin at 0.03 units/minute and titrate up by 0.005 units/minute every 10-15 minutes to a maximum of 0.1 units/minute, targeting a mean arterial pressure of 65 mmHg or higher. 1

Initial Dosing Protocol

The FDA-approved dosing for post-cardiotomy shock provides clear guidance 1:

  • Starting dose: 0.03 units/minute
  • Titration: Increase by 0.005 units/minute every 10-15 minutes
  • Maximum dose: 0.1 units/minute (limited data exist above this threshold)
  • Target: Mean arterial pressure ≥65 mmHg

Preparation and Administration

Dilute the 20 units/mL vasopressin injection in either normal saline (0.9% sodium chloride) or 5% dextrose in water prior to intravenous administration. Discard any unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration 1.

Clinical Context and Evidence

The 2019 EACTS/EACTA/EBCP guidelines establish the framework for managing vasoplegic syndrome during and after cardiopulmonary bypass 2. Vasoplegic syndrome during CPB should be treated with α1-adrenergic agonist vasopressors as first-line therapy (Class I recommendation). However, when patients are refractory to α1-adrenergic agonists, alternative drugs including vasopressin, terlipressin, or methylene blue should be used, either alone or in combination (Class IIa recommendation) 2.

The most recent 2024 EACTS guidelines reinforce this approach, recommending that vasoplegic syndrome during CPB be treated with α1-adrenergic agonists and/or vasopressin (Class I recommendation) 3. This represents an evolution from earlier guidelines that positioned vasopressin primarily as rescue therapy.

Evidence Supporting Vasopressin as First-Line Therapy

The landmark VANCS trial (2017) provides the strongest evidence for vasopressin use in post-cardiac surgery vasoplegia 4. In this randomized, double-blind trial of 300 patients, vasopressin (0.01-0.06 U/min) compared to norepinephrine (10-60 μg/min) resulted in:

  • Significantly reduced composite morbidity/mortality: 32% vs 49% (HR 0.55,95% CI 0.38-0.80, P=0.0014)
  • Lower incidence of atrial fibrillation: 63.8% vs 82.1% (P=0.0004)
  • No difference in digital ischemia, mesenteric ischemia, or myocardial infarction

A more recent 2026 randomized trial confirmed these findings, demonstrating that a vasopressin-based strategy (0.01-0.1 U/min) significantly reduced hospital length of stay (median 7.0 vs 8.0 days, P=0.0036) and provided superior hemodynamic stabilization compared to norepinephrine 5.

Critical Caveat: Left Ventricular Dysfunction

Exercise caution when using vasopressin in patients with severe preoperative left ventricular dysfunction (LVEF ≤35%). A 2018 propensity-matched study found that in this specific population, vasopressin did not improve outcomes compared to norepinephrine and was associated with higher rates of atrial fibrillation (20.12% vs 11.83%, P=0.038) and ventricular arrhythmias (24.85% vs 14.20%, P=0.014) 6. In these patients, norepinephrine remains the safer first-line choice.

Weaning Protocol

After target blood pressure has been maintained for 8 hours without catecholamines, taper vasopressin by 0.005 units/minute every hour as tolerated to maintain target blood pressure 1. This gradual weaning approach minimizes rebound hypotension.

Practical Algorithm

Step 1: Confirm vasoplegic syndrome (MAP <65 mmHg despite adequate fluid resuscitation, cardiac index >2.2 L/min/m²)

Step 2: Assess left ventricular function

  • If LVEF >35%: Start vasopressin 0.03 units/minute
  • If LVEF ≤35%: Start norepinephrine 0.025-0.2 μg/kg/min; reserve vasopressin for refractory cases

Step 3: Titrate vasopressin by 0.005 units/minute every 10-15 minutes until MAP ≥65 mmHg (maximum 0.1 units/minute)

Step 4: If inadequate response at maximum vasopressin dose, add norepinephrine or consider rescue therapy (methylene blue, hydroxocobalamin, or terlipressin) 2, 3

Step 5: Once stable for 8 hours, wean by 0.005 units/minute hourly

Common Pitfalls

  • Dosing too aggressively: The median effective dose in the VANCS trial was 0.06 U/min 4; most patients don't require maximum doses
  • Ignoring cardiac function: Vasopressin increases afterload and can worsen cardiac output in patients with severe LV dysfunction 6
  • Delaying initiation: Early vasopressin use (rather than waiting for catecholamine failure) appears more beneficial based on recent evidence 5, 7
  • Inadequate dilution: Always dilute the 20 units/mL stock solution before administration to prevent dosing errors 1

References

Related Questions

What is the initial management for postoperative vasoplegia?
Can vasopressin be used to raise blood pressure in a patient with refractory hypotension?
Should vasopressin be added when norepinephrine is at 15 µg/min to maintain target mean arterial pressure?
In a post‑anastomosis patient with postoperative hypotension or low cardiac output, should epinephrine be used as the first‑line vasopressor before vasopressin?
What is the recommended first-line vasopressor for intra‑operative correction of hypotension and its dosing?
What are the causes of a splenic artery aneurysm in a patient after splenectomy and partial pancreatectomy?
Is levofloxacin safe to use in patients with atrial fibrillation, and what dosing, renal adjustment, and ECG monitoring are recommended?
In a patient with idiopathic compensated hemolysis, mild splenomegaly, and cardiac changes, which laboratory and imaging studies should be performed and how often should they be repeated for monitoring?
How can I explain the use of low‑dose clonidine for patients with anxiety and elevated blood pressure in a simple way?
Can periodic worsening and improvement of fetal blood flow be observed during Doppler assessment?
How do I distinguish otitis interna (inner ear infection) from otitis externa (outer ear infection) and what are the first-line treatments for each?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.